Moderna Inc. (MRNA)
34.45
-0.26 (-0.75%)
At close: Mar 18, 2025, 11:42 AM
-0.75% (1D)
Bid | 32.83 |
Market Cap | 13.29B |
Revenue (ttm) | 3.24B |
Net Income (ttm) | -3.57B |
EPS (ttm) | -9.28 |
PE Ratio (ttm) | -3.71 |
Forward PE | -5.07 |
Analyst | Hold |
Ask | 34.95 |
Volume | 2,795,690 |
Avg. Volume (20D) | 11,818,510 |
Open | 34.49 |
Previous Close | 34.71 |
Day's Range | 33.59 - 35.00 |
52-Week Range | 29.25 - 170.47 |
Beta | 1.86 |
About MRNA
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus...
Industry Biotechnology
Sector Healthcare
IPO Date Dec 7, 2018
Employees 5,800
Stock Exchange NASDAQ
Ticker Symbol MRNA
Website https://www.modernatx.com
Analyst Forecast
According to 20 analyst ratings, the average rating for MRNA stock is "Hold." The 12-month stock price forecast is $50.5, which is an increase of 46.61% from the latest price.
Stock ForecastsNext Earnings Release
Moderna Inc. is scheduled to release its earnings on May 1, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 week ago
+15.94%
Moderna shares are trading higher after CEO Stepha...
Unlock content with
Pro Subscription
1 week ago
+0.33%
Moderna shares are trading higher after Stephane Bancel Disclosed a share purchase.